Side-by-side · Research reference
HGH Fragment 176-191vsProstamax
Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.
AAnimal-StrongHUMAN-REVIEWED28/59 cited
BAnimal-MechanisticHUMAN-REVIEWED11/38 cited
HGH Fragment 176-191
GH Fragment · Pre-Clinical
SQ · IP (animal) · Oral (tested)
Prostamax
Khavinson Bioregulator · Tissue-Specific Peptide
4 AAPeptide length
SQ · Protocol per Khavinson tradition
01Mechanism of Action
Parameter
HGH Fragment 176-191
Prostamax
Primary target
Beta-3 adrenergic receptors on adipocytesHeffernan 2001
Chromatin in prostatic cells — pericentromeric heterochromatin regions
Pathway
Fragment → β3-AR upregulation → Enhanced lipolytic sensitivityHeffernan 2001
Epigenetic modulation → heterochromatin decondensation → transcriptional derepressionDzhokhadze 2012
Downstream effect
Increased lipolysis and beta-3 AR mRNA expression without IGF-1 axis activation
Increased sister chromatid exchange, Ag-NOR activation, reduced C-heterochromatin condensation; tissue-specific regenerative stimulation in prostate organotypic culturesDzhokhadze 2012Zakutskiĭ 2006
Feedback intact?
N/A — does not interact with GH/IGF-1 axis
—
Origin
Synthetic peptide derived from hGH residues 176-191; AOD9604 includes N-terminal tyrosine (177-191)Cox 2015
Synthetic tetrapeptide modeled on naturally occurring protein-derived bioregulators isolated between lysine-arginine motifs in long-lived speciesKhavinson 2017
Antibody development
Not reported in available studies
—
02Dosage Protocols
Parameter
HGH Fragment 176-191
Prostamax
Animal dose (IP)
Not specified (14-day chronic administration)Heffernan 2001
Obese mice, daily IP injection.
—
Human equivalent dose
Not established — no published human RCTs
—
Frequency
Once daily (animal models)
—
Evidence basis
Animal studies only
Animal / organotypic cultureZakutskiĭ 2006Dzhokhadze 2012
No randomized controlled trials in humans.
Detection window
50 pg/mL LOD in urine; stable metabolite extends detectionCox 2015
WADA-banned; anti-doping testing available.
—
Oral bioavailability
Demonstrated efficacy in animal oral administrationNg 2000
Potential for oral therapeutic development.
—
Effective concentration (in vitro)
—
0.05 ng/mLZakutskiĭ 2006
Organotypic culture model; demonstrated tissue-specific stimulation.
Human clinical dose
—
Not established
No published human trials; dosing extrapolated from Russian clinical tradition (not peer-reviewed).
Age groups studied
—
Young (3-week) and aged (18-month) rats; elderly humans (75–86 years) in vitroZakutskiĭ 2006Dzhokhadze 2012
Duration
—
Not specified
Khavinson protocols typically 10–20 days per cycle; no long-term safety data.
03Metabolic / Fat Loss Evidence
Parameter
HGH Fragment 176-191
Prostamax
Weight gain reduction
50% reduction vs control (15.8 ± 0.6 g vs 35.6 ± 0.8 g)Ng 2000
Obese Zucker rats, 19 days oral administration.
—
Body fat reduction
Significant decrease in body weight and body fat in obese mice (14 days)Heffernan 2001
—
Lipolytic activity
Increased adipose tissue lipolytic activityNg 2000
Direct measurement in treated animals.
—
Insulin sensitivity
No adverse effect — euglycemic clamp confirmedNg 2000
Contrasts with intact hGH diabetogenic effects.
—
IGF-1 impact
No elevation — fragment does not activate GH/IGF-1 axis
—
Beta-3 AR dependency
Effect abolished in β3-AR knockout miceHeffernan 2001
Confirms β3-AR as primary mechanism.
—
Human evidence
None published — pre-clinical only
—
04Side Effects & Safety
Parameter
HGH Fragment 176-191
Prostamax
Human safety data
Not available — no published human trials
Absent — no published Phase 1/2/3 trials
Metabolic profile
Six metabolites identified; CRSVEGSCG most stableCox 2015
Detection window implications for doping control.
—
Published adverse events
—
None reported in available literature
Genotoxicity signals
—
Increased sister chromatid exchange (SCE) — marker of DNA recombination/repair; unclear long-term implications
Metal ion interactions
—
Modulates Cu(II) and Cd(II) chromatin effects; unknown clinical relevance
Absolute Contraindications
HGH Fragment 176-191
- ·Competitive athletes (WADA-banned)Cox 2015
Prostamax
- ·Active prostate malignancy — epigenetic modulation effects unknown in cancer
Relative Contraindications
HGH Fragment 176-191
- ·Absence of human safety data — experimental use only
Prostamax
- ·History of prostate cancer — theoretical concern re: transcriptional activation
- ·Undiagnosed prostatic nodules or elevated PSA
05Administration Protocol
Parameter
HGH Fragment 176-191
Prostamax
1. Route
Subcutaneous injection primary route in research context. Oral administration demonstrated efficacy in animal models at 500 mcg/kg.
Subcutaneous or intramuscular — per Khavinson bioregulator tradition. No published human pharmacokinetic data.
2. Frequency
Once daily dosing used in animal studies. Timing not specified; GH-independent mechanism suggests flexibility.
If lyophilised: reconstitute with sterile water per manufacturer protocol (not standardized in literature).
3. Duration
Animal protocols: 14–19 days. Human duration not established — no published trials.
Typically daily or every-other-day in Russian clinical tradition; duration 10–20 days per cycle.
4. Storage
Lyophilized peptide storage per standard peptide protocols. Metabolite stability suggests refrigerated reconstituted solution viable.
No established biomarkers. Theoretical: PSA, prostate imaging, symptom scores (IPSS for BPH).
5. Detection
Detectable in urine via SPE-LC-MS at 50 pg/mL LOD. Extended detection window via stable metabolite CRSVEGSCG.Cox 2015
All protocols derived from non-peer-reviewed Russian clinical practice; Western regulatory approval absent.